Clinical Trial

Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial

Name: Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial — clinical trial record (NCT07245316)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ASAIN

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received endocrine therapy.

Trial Details

NCT Number	NCT07245316
Lead Sponsor	Jeong Eon Lee
Conditions	Ductal Carcinoma in Situ of the Breast
Enrollment	340 participants
Start Date	2025-12-01
Primary Completion	2032-12-31 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-11-24